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Sul-lrlmary 
Recombinant human tumor necrosis factor-o~ (TNF-c~) has demonstrable antitumor activity in 
transplantable murine tumor models and patients with cancer but is highly toxic to both animals 
and human beings. The narrow therapeutic index of TNF-cx has limited its anticancer utility. 
Toxicity associated with many standard anticancer drugs is highly dependent upon the circadian 
timing of their administration. The effect of time of day of TNF-o~  administration on lethal 
toxicity was examined in 238 BALB/c female mice in two studies. Each mouse received a single 
intravenous injection of human TNF-c~ at one of six equispaced times within the first contiguous 
24-h cycle. The probability of dying across all times of day of TNF-c~ treatment was not equal 
(p <0.01) and varied up to ninefold. Significant time of day dependence of TNF-cx toxicity was 
present over a full order of magnitude of TNF-ot dose. The frequency of TNF-a-induced lethality 
was greatest and the time to death was most brief when TNF-a was administered just before 
awakening. The survival probability was highest when TNF-o~ was administered in the second 
half of the daily activity span corresponding roughly to late afternoon and evening hours for 
human beings. The optimization of TNF-c~ administration timing is a strategy that warrants 
further investigation for improving the toxic/therapeutic ratio of this important cytokine. From 
a more fundamental perspective, these data may be essential for achieving a fuller understanding 
of TNF-o~  in vivo biology. 
T 
NF-ot has emerged as an important regulator of inflam- 
mation being one of the mediators of acute phase reac- 
tions,  endotoxic shock, cachexia of chronic disease  states, 
and ceU-mediated host  defense against  bacteria,  parasites, 
and tumor cells (1, 2). TNF-ol induces hemorrhagic necrosis 
and regression of a variety of transplantable murine and human 
tumors (3-5). The mechanisms responsible for the antitumor 
action of TNF-ol include both direct toxic effects upon tumor 
cells (6), indirect host-mediated procoagulant (7), and im- 
munomodulatory effects which require host immune com- 
petency (4). 
Therapeutically, recombinant human TNF-c~ has been in- 
vestigated as a potential anticancer agent over the last decade 
for the treatment of patients with advanced cancer. Phase I 
clinical studies in cancer patients have, however, been daunting 
because  of  the  severity  of TNF-c~  toxicity  (8-10).  The 
endotoxin-like toxicities uniformly include hemodynamic in- 
stability, fever, diarrhea, metabdic acidosis, capillary leak syn- 
drome, induction of a catabolic state, neurotoxicity, and renal 
and hematologic toxocity which severely limit drug dosing. 
At the same time, responses have been very infrequent with 
only minimal or partial responses observed. 
These  experimental and  clinical  data  demonstrate that 
TNF-c~ can act either as a therapeutic tool or as a lethal toxic 
agent (11, 12). The narrow therapeutic index of TNF-o~ has 
encouraged the development of strategies to diminish tox- 
icity while hopefully preserving antitumor activity. Several 
approaches include use of continuous infusions (13), glucocor- 
ticoids  (14),  inhibitors  of  prostaglandin  synthesis  (15), 
scavengers of oxygen radicals  (16),  and combining TNF-ot 
with cytotoxic chemotherapy (17) or other cytokines (18). 
Toxicity still remains the most significant limitation to TNF-c~ 
therapeutic utility. 
The toxicity of many standard cytotoxins in animals and 
humans can be reduced and dose intensity increased by ap- 
propriate circadian timing (19).  In animal studies, optimal 
circadian drug timing has consistently been associated with 
maintenance of antitumor activity and has often improved 
tumor responses (20). In view of these findings and the real- 
ization that few, if any, biological processes do not partici- 
pate in high-amplitude circadian rhythms, we examined the 
effect of circadian timing of TNF-o~ administration on lethal 
toxicity in BALB/c mice. 
Materials  and Methods 
Animals and Chronobiologic Study Design.  Female  BALB/c mice 
(Harlan Sprague Dawley, Inc., Indianapolis, IN), 8-10- (Study 1) 
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to five per cage in three sound-dampened rooms under 12-h on, 
12-h off light/dark schedules. The timing of these lighting regi- 
mens was staggered by 8 h in each of three different rooms. Time 
is referenced to as hours after light onset (HALO) 1  with lights on 
during the 0-12 HALO putative sleep span and lights off during 
the 12-24 HALO putative activity span of these nocturnal animals. 
Food and deionized water were freely available. Temperature and 
humidity were nearly constant at 24 _+ 1~  and 40 _+ 2%, respec- 
tively. Very low lux overhead red lights were used during the dark 
span to minimize animal disturbance and to facilitate human move- 
ment. Mice were standardized under these conditions  for 3 wk 
before study. Circadian synchrony was documented by demonstra- 
tion of the characteristic 24-h pattern in core body temperature 
before each experiment. 
Cytokine Treatment.  Recombinant human TNF-ot was provided 
by Cetus Corp. (Emeryville, CA) as a lyophilized powder, and was 
>95% pure before lyophilization. Vials were reconstituted in PBS, 
pH 7.4, and stored -70~  before intravenous injection. Lot #TD 
4 (1.3  x  107 U/rag sp act by the routine L929 assay) was used 
in Study 1. Lot #NP 102 (1.8  x  107 U/rag sp act) was used in 
Study 2. Animals were given a single intravenous bolus injection 
of TNF-ot in 0.1-0.15 cc by tail vein at various doses (Million Units 
(MU)/kg body weight).  Injections were performed at one of six 
equispaced circadian times (02, 06, 10, 14, 18, and 22 HALO) within 
the initial 24-h cycle. 
Toxicity Study Design.  Two large studies each involving the in- 
vestigation of six groups  of female BALB/c mice treated at one 
of six times spaced by 4-h intervals during the initial 24-h span 
were performed. In Study 1, a total of 119 mice were studied. Each 
of the six circadian treatment groups were randomly divided into 
four subgroups of five animals each (except for the 06 HALO group 
with 10 MU/kg, 4 mice were injected). Each subgroup received 
one of four randomly assigned doses of TNF-ot (3.3, 6.7,  10.0, 
or 13.3 MU/kg). In Study 2, a total of 119 mice were studied. 
Each of the six circadian treatment groups was randomly divided 
into two subgroups of 10 animals each (except for the 02 HALO 
group with 27.0 MU/kg, nine mice were injected). Each subgroup 
received one of two doses of TNF<z (18.0 or 27.0 MU/kg). The 
final number of animal deaths per group (percent mortality)  and 
the time to death  (hours) after TNF-ot injection of each animal 
(survival time) was recorded. Toxicity was assessed by inspecting 
cages every 2 h for animal deaths for up to 4 d. Proportional sur- 
vival analyses were performed with data truncated at the time of 
last toxic death  (98 h for Study 1 and 62 h for Study 2). 
Statistical Analysis.  For each study, the proportion of animals 
dead in each subgroup was compared by chi squared (X 2) analysis. 
The percent survivors as a function of either dose or treatment 
timing was also evaluated by Kruskall-Wallis (KW) life table anal- 
ysis. Analyses of variance (ANOVA, F value) were employed to 
determined the effects of TNF-ot dose and circadian time of TNF- 
ot injection upon survival time. The presence of circadian (sinu- 
soidal) rhythm was assessed for the proportion of the treatment 
groups surviving and for the survival times by the cosinor least 
squares methods.  (21). 
LDso.  The lethal  dose  for  50%  mortality  (LD50, dose  of 
TNF-ot that kills 50% of animals) is calculated by treating groups 
of animals with different doses across a range of doses that kills 
from a small minority of the exposed animals to well over half of 
them. Equal groups of the 238 mice in our study were treated with 
1 Abbreviations used in this paper: ANOVA, analysis of variance; HALO, 
hours after light onset; KW, Kruskall-Wallis; MU, Million units. 
one of six TNF doses covering an order of magnitude of TNF-o~ 
(from ,,o3 to '-30 MU/kg) and at each of six equispaced times 
of day. To determine the relationship between dose and lethality, 
the mortality achieved at each dose was plotted against that dose 
and a line was fit by the process of least squares. This process was 
repeated for all dose groups treated at each of the six times of day 
yielding  six  separate lethality  relationships  with  correlation 
coefficients (R) and six LD50 estimates. Linear regression of data 
grouped from treatments during sleep phase versus treatment during 
activity phase were also performed for calculation of LD50 of these 
grouped data. 
Results 
Toxicity Studies 
Survival Time Analysis.  Time to death (survival time) trun- 
cated at the moment of last toxic death in each study was 
analyzed for dose and time of day effects. The mean survival 
times of these mice depend both upon the time of day of 
TNF-ot administration,  and upon the dose of TNF-cz ad- 
ministered.  As  expected, the greater the TNF-ot dose the 
shorter the survival time. A two-way ANOVA of the trun- 
cated survival time of  mice treated with different TNF-ot doses 
from each study separately and from both studies combined 
demonstrates a significant circadian time effect (Fig. 1 A, F  = 
7.1, p  =  0.0001) as well as significant TNF-ot dose-effect 
(Fig.  1 B, F  =  51.4, p  =  0.0001). An interaction between 
these two factors was also prominent (F  =  2.5, p <0.001), 
demonstrating that dose and timing have complex relations 
to mortality; e.g., lower doses at some times of  day have greater 
lethality than much higher doses at other times of day. The 
mean truncated survival time of mice injected during the sleep 
span (02, 06, and 10 HALO) is much lower (43 h versus 68 h) 
than when the agent is given during the activity span (14, 
18,  and 22 HALO).  The toxicity of TNF-ot is greatest at 
06 and 10 HALO (sleep phase) as evidenced by shorter sur- 
vival times than at 14 and 18 HALO (late activity phase). 
Regardless  of dose,  time of day of TNF-ot treatment was 
responsible for a 1.5-2-fold variation in survival times. The 
optimal times would approximate late afternoon and early 
evening for a diurnally active human being. 
Analysis of Final Proportional Survival.  Percent overall mor- 
tality as a function of the time of day mice received TNF-cz 
and the dose of TNF-ot was analyzed by X  2 analyses for each 
study (Table  1). In Study 1,  overall  mortality ranged from 
10 to 38% for all TNF-ot doses. A significant circadian treat- 
ment time effect (X  z =  15.8, p  =  0.008) was demonstrated 
for the frequency of final overall mortality across  all doses 
of TNF-ot. The most statistically significant circadian time- 
dependent toxicity (X  2 --  19.0, p  ---  0.002) was seen at 10.0 
MU/kg dose of TNF-ot, where 100% of the mice died when 
treated just before daily awakening (10 HALO). This is con- 
trasted to a total lack of mortality when mice receive the same 
dose of TNF-ot during the middle of the activity span (18 
HALO). Across all doses, mice treated during the second half 
of their daily activity phase (18 HALO) died less frequently 
(10% mortality), whereas mice treated  just before awakening 
(10 HALO) showed a much higher final lethality (55% mor- 
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Figure 1.  Observed  survival 
time in hours (mean _+ SEM) after 
TNF-a administration truncated at 
the time of last toxic animal death. 
(.4) Survival time, across all TNF- 
cx doses, of mice (Study 1 and Study 
2 combined) as a function  of the 
time of day (HALO) TNF-a was 
administered is shown. A significant 
time of day of treatment  effect is 
seen across one entire log of TNF-ot 
dose  by  ANOVA (F  =  7.1, iv 
<0.0001).  Survival time  varied 
nearly twofold whether these stud- 
ies were analyzed separately or to- 
gether as shown here. The shortest 
survival time is seen when TNF-~x 
is given just before daily awakening (10 HALO).  (B) Survival time, across all times of day of TNF-oe administration, of mice as a function of dose 
of TNF-c~. A significant dose-effect is seen by ANOVA (F  =  51.4, p <0.0001) with higher doses resulting in shorter survival times. 
Table  1.  Percent  Mortality as a Function of the Time of Day of Administration (HALO) and Dose of TNF-ce 
Time of Administration  (HALO)  X  2 analysis 
Dose  Mortality 
(MU/kg)  2  6  10  14  18  22  (All HALO)  X  2  p  value 
Study  1 
Study 2 
Study 2 
Truncated  at time of last death 
3.3  20  0  0  0  20  40*  13.3  5.8  0.330 
(1/5)  (0/5)  (0/5)  (1/5)  (2/5)  (2/5)  (4/30) 
6.7  0  20  40  0  0  0  10.0  7.8  0.170 
(0/5)  (1/5)  (2/5)  (0/5)  (0/5)  (0/5)  (3/30) 
10.0  0  25  100  80  0  20  38.0  19.0  0.002 
(0/5)  (1/4)  (5/5)  (4/5)  (0/5)  (1/5)  (11/29) 
13.3  20  40  80  0  20  20  30.0  9.0  0.110 
(1/5)  (2/5)  (4/5)  (0/5)  (1/5)  (1/5)  (9/30) 
All doses  10  21.1  55  20  10  20  22.7  15.8  0.008 
(2/20)  (4/19)  (11/20)  (4/20)  (2/20)  (4/20)  (27/119) 
Truncated  at time of last death 
18.0  90  100  50  30  60  40  61.7  16.4  0.006 
(9/10)  (10/10)  (5/10)  (3/10)  (6/10)  (4/10)  (37/60) 
27.0  78  100  100  60  80  60  79.7  9.9  0.078 
(7/9)  (10/10)  (10/10)  (6/10)  (8/10)  (6/10)  (47/59) 
All doses  84.2  100  75  45  70  50  70.6  20.6  0.001 
(16/19)  (20/20)  (15/20)  (9/20)  (14/20)  (10/20)  (84/119) 
Truncated  at 50%  mortality 
18.0  70  90  50  30  40  20  50.0  13.6  0.018 
(7/10)  (9/10)  (5/10)  (3/10)  (4/10)  (2/10)  (30/60) 
27.0  56  100  80  30  20  30  53.0  20.4  0.001 
(5/9)  (10/10)  (8/10)  (3/10)  (2/10)  (3/10)  (31/59) 
All doses  62.8  95.0  65  30  30  25  51.3  34.7  0.0001 
(12/19)  (19/20)  (13/20)  (6/20)  (6/20)  (5/20)  (61/119) 
* Percentage of mice dying after each dose of TNF-c* administered at the referenced time of day in each study with number of dead mice/total 
mice shown in parentheses. 
1061  Hrushesky et al. tality).  In  Study 2,  overall  mortality  reached  62-80%.  A 
significant circadian time-dependent effect (X  2 =  20.6, p  = 
0.001) was also demonstrated  for percent  overall mortality 
of mice (Table 1). Mice treated during the activity phase (14, 
18, and 22 HALO) showed lower mortality,  whereas mice 
treated during the sleep span (02, 06, and 10 HALO) showed 
much higher  mortality. 
Life Table  Analysis of  Percent Survivors Over Time.  KW life 
table analysis  of percent  survivors over time was analyzed 
for Study 2. A  significant difference in overall  survival pat- 
tern was seen with TNF-c~ dependent upon the time of day its 
administration for both the 18.0 MU/kg dose (KW score = 
19.7,  p  <0.002;  Fig.  2  A)  and  the  27.0  MU/kg  dose 
(KW score =  17.4, p <0.05, Fig. 2 B). At both doses, mice 
treated in the middle and second half of the daily sleep span 
(06-10 HALO) died earlier and more frequently than those 
mice treated  in  the activity span  (14-22  HALO). 
LDso Analysis and Mortality Truncated at 50%.  The le- 
thal dose for 50%  survival (LDs0) was calculated from the 
results of all doses by linear regression of the dose-mortality 
relationship  separately for each time of day of TNF  treat- 
ment and for treatment in the light phase or in the dark phase. 
Results  for  LDs0  estimates  were  15.9,  13.5,  and  12.9 
MU/kg for treatment at 02, 06, and 10 HALO, respectively, 
and  14.1  MU/kg  for  treatment  in  the  sleep phase  (R  = 
0.79, p <0.001) compared with 24.0, 17.8, and 20.2 MU/kg 
for treatment at 14, 18, and 22 HALO, respectively, and 19.9 
MU/kg  for  treatment  in  the  activity  phase  (R  =  0.83, 
p <0.001).  Mice  treated  late  in  their  activity phase  toler- 
ated much higher doses than mice treated just before early 
awakening.  There was almost a twofold difference in LDs0 
(13 MU/kg vs. 24 MU/kg), depending solely upon the time 
of day that  this cytokine was administered. 
Proportional survival truncated when 50% of animals have 
died is an alternative  way to look at  time-dependent  mor- 
tality. Since >50% mortality was achieved only in the Study 
2, mortality truncated at 50% overall mortality was analyzed 
for this study (Table 1). Mice injected during the activity span 
(14-22 HALO) showed two to threefold lower mortality than 
those injected during the sleep span (02-10 HALO) assessed 
by percent mortality. The highest mortality of TNF-ot was 
observed when  administered  at 06 HALO (95%)  and the 
lowest mortality was seen when TNF-c~ was administered 
at 22 HALO (25%).  The pattern  and magnitude of these 
results  are  in  accord  with  the  LDso  calculations  derived 
above. 
Circadian Rhythm Analysis 
Cosinor least squares analysis of a 24-h period fit was per- 
formed on the truncated survival time of TNF-ot-treated mice 
(Table 2).  In Study 1, a significant 24-h rhythm in TNF-ot 
toxicity was found when all doses were examined together 
(p  =  0.052). Across all doses, the time of day of treatment 
predicted for maximal  survival (acrophase) is at end of the 
activity span (21:19 HALO). This same time of day was con- 
sistently found for each of the larger TNF-ot doses. The lowest 
TNF-ot dose (3.3 MU/kg), which killed only a tenth of the 
mice, predicted a somewhat different time of day for max- 
imum survival time in the late sleep span (10:00).  For Study 
2,  where  overall  mortality  consistently  exceeded  50%,  a 
significant 24-h rhythm of TNF-ot toxicity was also found 
(p <0.001). The predicted time of day for maximum survival 
(acrophase)  was  also  found  in  mid-to-late  activity  (17:52 
HALO). In both studies, the amplitude of the 24-h TNF-oe 
toxicity rhythm was greater with higher doses of TNF-ot, 
implying a greater proportion of the variability in toxicity 
was attributable to time of day-dependent differences.  These 
analyses indicate that the safest time for TNF-ot may be mid- 
to-late in the daily activity span, a time comparable to 4-10 
p.m.  for diurnally active human beings. 
Discussion 
At the end of last century, the medical community began 
paying attention  to the therapeutic approach of Coley (22) 
who treated malignant  tumors with repeated injections of 
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Figure 2.  Life  table analysis of 
percent survivors over time after 
TNF-o~ is demonstrated as a func- 
tion of time of day of administra- 
tion (Study 2).  TNFoc~ was ad- 
ministered at one of six times within 
the first 24-h cycle  at a dose of 18.0 
(.4) or 27.0 MU/kg (B). Kruskall- 
Wallis analyses reveal a significant 
difference  in the proportion of sur- 
vigors dependent  upon when within 
the day TNF-a is administered for 
both the 18.0 MU/kg dose (KW 
value  =  19.7, p <0.002) and the 
27.0 MU/kg dose (KW value = 
I7.4, p <0.05). Mice given TNF-~ 
during the sleep span (02, 06, 10 
HALO) have threefold higher survival rates than mice given TNF-ot in the activity span (14, 18, 22 HALO). The number at the base of each survival 
curve is the final percentage of survivors truncated at 62 h (time of last death) for each HALO of treatment. 
1062  Circadian  Dynamics of TNP-ot (Cachectin) Lethality Table  2.  Cosinor Analysis of the Time of Day (HALO) Dependence of Survival Time (h) of Mice after TNF-cr Administration 
Dose  No. of 
(MU/kg)  Mice  p Value  Mesor  Amplitude  Acrophase (HALO) 
h 
Study 1  3.3  30  0.073  87.4  +_  4.9*  16.8  _+  7.0*  10:00  _+  1:36  s 
6.7  30  0.086  90.5  _+  4.3  14.1  _+  6.1  20:30  _+  1.42 
10.0  29  0.012  75.1  _+  5.9  26.7  _+  8.2  22.42  _+  1:12 
13.3  30  0.130  74.7  _+  6.7  19.8  _+  9.4  20.33  _+  1:48 
All doses  119  0.052  82.0  _+  3.0  10.3  +  4.2  21:19  _+  1.53 
Study 2  18.0  60  <0.001  38.2  +__ 2.5  15.3  _+  3.5  17:16  _+ 0:54 
27.0  59  <0.001  28.6  _+  2.3  17.0  _+  3.2  18:23  _+  0.42 
All doses  119  <0.001  33.5  _+  1.7  16.0  _+  2.5  17:52  _+  0:36 
Cosinor analysis was performed with a 24-h period fit. 
* Mesor, 24-h adjusted mean for the survival time (h). 
* Amplitude, half  the difference  between maximal and minimal values for survival time. 
S  Acrophase, time of day expressed in HALO for the maximum  predicted  survival time that was most consistently  between 17:00 and 22:00 HALO 
(mid to late sleep). Values are given with the standard error. 
bacterial cultures. Later, the immune and inflammatory reac- 
tions, known as the Shwartzman phenomenon, associated 
with bacterial toxin administration, were observed to be as- 
sociated with local and sometimes generalizable  anticancer 
effects (23, 24). A tenacious search for the factors responsible 
for the tumor hemorrhage associated  with the administra- 
tion of these toxins concluded with the identification and 
isolation of endotoxins. Associated with these toxin exposures 
was the release of a series of powerful cytokines. TNF-ot was 
finally identified as a prominent component of this inflam- 
matory process  (25,  26).  It was found that TNF-cz could 
reproducibly cause shrinkage of and even cure transplantable, 
chemically induced cancers (meth-A sarcoma) in BALB/c mice 
(27). The therapeutic responses in animals and humans, how- 
ever, have usually been achieved at doses of  TNF-ot approaching 
those associated with endotoxin-induced shock (2,  11,  12). 
We have found that the timing within the day of TNF-ot 
administration to BALB/c mice is responsible for up to a nine- 
fold difference in the frequency of lethal toxicity and time 
to death over a range of TNF-ot doses. As the dose of TNF-ot 
increased,  the time of day difference in this predictable tox- 
icity rhythm becomes greater.  In light of the central impor- 
tance of TNF-ot in mediating endotoxin-induced lethality, 
it is interesting to note a circadian-timed endotoxin study 
done more than 30 yr ago. Halberg et al. (28) reported that 
the susceptibility of mice to Escherichia coli endotoxin-induced 
lethality varied significantly and predictably throughout the 
day. When endotoxin was administered during the activity 
span, a 10-fold-lower mortality of BALB/c mice reproducibly 
occurred. This finding accurately predicts and is coincident 
with the circadian toxicity pattern for TNF-tx demonstrated 
here. In D-galactosamine-loaded mice (to enhance endotoxin 
susceptibility), a ninefold difference in the susceptibility to 
endotoxin or monophosphoryl lipid A-induced lethal tox- 
icity was seen with greatest toxicity when the agents were 
administered at the sleep-wake border (29). The diurnal vari- 
ation in endotoxin toxicity reported with D-galactosamine- 
loaded mice was paralleled by circadian-dependent elevations 
in serum TNF-a levels. 
TNF-t~ is clearly a final common pathway for the induc- 
tion of endotoxin-associated shock secondary to sepsis. It is 
interesting to note that hospital deaths, many associated with 
sepsis, do not occur randomly throughout the day but are 
more frequent between 2 a.m. and 6 a.m. (30).  This time 
of day corresponds to the time in the circadian  cycle when 
endotoxin and TNF<x are each most frequently lethal. The 
recognition and explanation of this time structure may well 
be helpful to the successful use of the many potential molec- 
ular blockers of sepsis-induced lethality that are currently under 
aggressive  clinical  study. 
The underlying mechanisms for this time of day toxicity 
are not known. The peak toxicity for TNF-ot and E. coli en- 
dotoxin both occur at the time of day that is close to the 
usual daily cortisol peak (31). Very large and reproducible 
circadian-dependent variations in the production and secre- 
tion of glucocorticoids, adrenocorticotropic hormone and 
growth hormone have been documented. These same hor- 
mones are also important in mediating the response to acute 
infectious and endotoxic challenge.  Pharmacological manip- 
ulation of glucocorticoid levels can influence the response to 
TNF-ot and endotoxin. Treatment of ceils in vitro with high 
doses of glucocorticoid can modulate the production of sev- 
eral inflammatory cytokines including TNF-t~ (32), ILl (33), 
IFN-  3, (34), and IL-2 (35). Adrenalectomy has been reported 
to sensitize mice to the lethal response to endotoxin (36, 37). 
Endotoxin causes increased glucocorticoid production and mice 
rendered tolerant to TNF in vivo have increased glucocorti- 
coid production. However, in normal animals,  glucocorti- 
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(38).  How well these extreme manipulations of glucocorti- 
colds relate to the endogenous circadian change in glucocor- 
ticoid levels is not clear. Hypophysectomy can increase the 
sensitivity  to  lethality  of bacterial  inoculation  (39)  and 
pituitary-hypophyseal-derived proteins appear  to modulate 
this response. Growth hormone protects hypophysectomized 
mice from lethal bacterial challenge (39), whereas pituitary 
production of macrophage migration inhibitory factor (MIF) 
or administration of MIF enhances the lethality of endotoxin 
(40). Serum levels oflL-1 vary throughout the day (41) which 
could conceivably modulate TNF effects and cytokine cas- 
cades. Mechanisms by which the normal physiologic circa- 
dian variation in the production of these hormones and their 
response to physiologic modulation contributes to circadian- 
dependent lethality of TNF and endotoxin warrant investi- 
gation. 
Other  mechanisms  may  also  contribute  to  circadian- 
dependent differences in TNF-oe-induced lethality. Daily vari- 
ations in the function of target tissues exist and could modu- 
late the susceptibility of these tissues  to TNF-ot-mediated 
toxicity. For example, circadian-dependent variations in the 
glutathione cycle activity (20), in immune cell function (42), 
bone marrow function (43), and tumor blood flow (44), have 
all been described. Time of day-dependent differences in pro- 
tein drug pharmacokinetics may also contribute to time of 
day toxicity profiles. 
Circadian timing of drug administration, as a strategy to 
alter dose-limiting toxicities, has been demonstrated in preclin- 
ical and clinical  studies with traditional agents.  Circadian 
timing of antitumor or hematopoietic cytokines may be an 
additional strategy to alter dose-limiting toxicities and/or im- 
prove  efficacy. The circadian  time structure of therapeutic 
cytokine administration is beginning to be investigated. My- 
elotoxicity and antitumor activity of IFN-oe and IFN-3' have 
been demonstrated to vary as a function of circadian  time 
of administration in mice (45-47).  The optimal time for min- 
imal myelotoxicity  and maximal antitumor activity were coin- 
cident for each type of IFN but with different optimal times 
of day for the two classes of IFNs. Hematopoietic growth 
factor efficacy also varies with the time of day of their ad- 
ministration (48).  Our current studies suggest that TNF-oe 
toxicity is highly dependent upon the time of  day of adminis- 
tration. Optimal circadian timing of TNF-oe administration 
might be a useful strategy to consider to increase dose inten- 
sity and possibly enhance antitumor efficacy. 
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